Infectious Diseases, Phase III

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Volunteers
Health Professionals

What is the purpose of this trial?

This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.

Trial with
Pfizer Inc., U.S. Pharmaceuticals Group
Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Laurie Andrews

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Jessica Tuan, MD, MS, AAHIVS
Assistant Professor of Medicine (Infectious Diseases); Affiliated Faculty, Yale Institute for Global Health; Associate Director, Yale Antivirals & Vaccines Research Program, Infectious Diseases

Sub-Investigators

Last Updated
04/21/2023
Study HIC
#2000033600